Rocket Pharmaceuticals (RCKT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
20 May, 2026Opening remarks and agenda
Chairman welcomed attendees and introduced board members and officers present in person and virtually.
Meeting called to order, with formal business to follow as outlined in the notice and proxy statement.
Corporate governance
Record date for stockholders set as March 24, 2026, with proper notice and documentation confirmed.
Tracy Oates appointed as Independent Inspector of Election to oversee voting and certify results.
Quorum established with proxies representing 74.2% of outstanding shares.
Shareholder proposals
Four proposals presented: election of seven directors, ratification of accounting firm, advisory vote on executive compensation, and approval of stock option exchange program.
No discussion or questions raised for any of the proposals.
Latest events from Rocket Pharmaceuticals
- Cardiac gene therapy pipeline advances with pivotal trials and major updates expected this year.RCKT
Jefferies Global Healthcare Conference 20264 Jun 2026 - Accelerated approval, $180M PRV sale, and reduced expenses extend cash runway into 2028.RCKT
Q1 20267 May 2026 - 2026 will see pivotal trial progress and potential first commercial launch in rare cardiac gene therapy.RCKT
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.RCKT
Proxy filing6 Apr 2026 - Shareholders will vote on directors, auditor, executive pay, and a stock option exchange program.RCKT
Proxy filing6 Apr 2026 - FDA grants accelerated approval to first gene therapy for severe pediatric LAD-I, pending trials.RCKT
FDA announcement2 Apr 2026 - Shareholders will vote on directors, auditor, executive pay, and a stock option exchange program.RCKT
Proxy filing25 Mar 2026 - Cardiac gene therapy pipeline advances with regulatory, commercial, and manufacturing milestones in 2026.RCKT
Leerink Global Healthcare Conference 202610 Mar 2026 - Biotech aims to raise $400M for rare cardiovascular gene therapies amid strategic refocus.RCKT
Registration Filing2 Mar 2026